Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Immunocompromised Participants
2022-002378-95Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of AZD5156 and sipavibart in coronavirus disease 2019 (COVID-19) and airway morbidity (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD5156/AZD3152 and Efficacy of AZD5156/AZD3152 for pre-exposure prophylaxis of COVID-19. Started Nov 2022; status: active.
02
Drugs
AZD5156sipavibart
03
Conditions
coronavirus disease 2019 (COVID-19)airway morbidity
Beyond the preview
Go deeper on 2022-002378-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002378-95.